EQS-News: M1 Kliniken AG: Strong Q1 2025 with 29% EBIT Growth and Earnings per Share of EUR 0.31
|
EQS-News: M1 Kliniken AG
/ Key word(s): Quarter Results/Quarterly / Interim Statement
M1 Kliniken AG: Strong Q1 2025 with 29% EBIT Growth and Earnings per Share of EUR 0.31 Berlin, 5 June 2025 – M1 Kliniken AG (ISIN: DE000A0STSQ8) has made a strong start to the 2025 financial year and continues its profitable growth trajectory. The significant improvement in earnings results from the consistent implementation of efficiency measures and the targeted expansion of medical capacities. Key Financials at a Glance
Beauty Segment: Profitability Further Increased
The Beauty segment remains the Group’s main earnings driver. In Q1, it benefited in particular from efficiency gains through optimized processes and higher utilization of medical capacity. A targeted pricing strategy helped attract new customer groups and support market share expansion, without impacting margin quality. M1 continues to pursue its positioning as a leading provider of high-quality aesthetic medicine at market-leading prices. Trading Segment: Double-Digit Growth in Revenue and EBIT
The trading segment continued its positive development in Q1, once again posting double-digit growth in both revenue and EBIT. Segment profitability was further improved. Outlook In 2025, M1 Kliniken AG aims to continue its profitable growth by expanding its network of national and international clinics. In the Beauty segment, full-year revenue is expected to range between EUR 100 million and EUR 120 million. By 2029, this figure is projected to grow to EUR 200 million to EUR 300 million, with a sustainably targeted EBIT margin of at least 20%. The Group is consistently pursuing its goal of establishing M1 Med Beauty as the world’s leading brand in aesthetic medicine. M1’s business activities remain unaffected by current geopolitical developments, as the Group has neither operational sites nor supply or service relationships in the affected regions. About M1 Kliniken AG M1 Kliniken AG is the leading fully integrated provider of medical aesthetic services in Europe and Australia. With a clear strategic focus, high standardization, and consistent scalability, the Group currently operates 58 clinics in ten countries under the M1 Med Beauty brand. All treatments are performed exclusively by qualified physicians and adhere to uniform, high medical standards, while being offered at market-leading prices. Since late 2018, M1 has systematically driven its international expansion, which forms the basis for scalable future growth and the further development of its global market position. With the M1 Schlossklinik in Berlin, the Group operates one of Europe’s largest and most modern clinics for plastic and aesthetic surgery, featuring four operating theaters and 35 beds. Contact: M1 Kliniken AG Grünauer Straße 5 12557 Berlin T: +49 (0)30 347 47 44 14 M: ir@m1-kliniken.de
05.06.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | M1 Kliniken AG |
| Grünauer Straße 5 | |
| 12557 Berlin | |
| Germany | |
| Phone: | +49 (0)30 347 47 44 14 |
| Fax: | +49 (0)30 347 47 44 17 |
| E-mail: | ir@m1-kliniken.de |
| Internet: | https://www.m1-kliniken.de |
| ISIN: | DE000A0STSQ8 |
| WKN: | A0STSQ |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2151076 |
| End of News | EQS News Service |
|
|
2151076 05.06.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 77,27 | 159,59 | 314,61 | 285,29 | 316,32 | 339,18 | 349,00 | |
| EBITDA1,2 | 11,33 | 8,89 | 17,82 | 15,41 | 21,01 | 31,96 | 33,70 | |
| EBITDA-Margin3 | 14,66 | 5,57 | 5,66 | 5,40 | 6,64 | 9,42 | 9,66 | |
| EBIT1,4 | 7,93 | 4,41 | 12,13 | 9,35 | 15,70 | 26,75 | 28,20 | |
| EBIT-Margin5 | 10,26 | 2,76 | 3,86 | 3,28 | 4,96 | 7,89 | 8,08 | |
| Net Profit (Loss)1 | 9,73 | 7,43 | 10,88 | 7,07 | 11,67 | 17,79 | 18,80 | |
| Net-Margin6 | 12,59 | 4,66 | 3,46 | 2,48 | 3,69 | 5,25 | 5,39 | |
| Cashflow1,7 | -5,37 | 9,54 | 15,68 | 20,77 | 7,81 | 30,55 | 24,50 | |
| Earnings per share8 | 0,56 | 0,37 | 0,45 | 0,22 | 0,54 | 0,85 | 0,93 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,50 | 0,50 | 0,50 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: wetreu NTRG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| M1 Kliniken | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A0STSQ | DE000A0STSQ8 | AG | 379,51 Mio € | 14.09.2015 | Kaufen | 9F4MCHV9+6R |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 15,58 | 27,45 | 0,57 | 44,93 | 3,94 | 12,42 | 1,12 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,50 | 0,50 | 0,50 | 2,59% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 16.07.2025 | 05.06.2025 | 09.09.2025 | 18.11.2025 | 21.05.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +28,84% | +31,86% | +16,39% | +20,37% | +311,06% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
